Unlocking the Potential of mRNA Therapies: A Revolutionary Partnership Shaping the Future of Medicine
Wacker Biotech and RNAV8 Bio partner to advance mRNA-based therapies, leveraging expertise in pDNA, mRNA production, and LNP formulation. RNAV8 Bio's innovative approach to mRNA engineering optimizes untranslated regions (UTRs)…
The Exciting Future of mRNA Therapies: A Game-Changing Partnership in Biomanufacturing
Wacker Biotech and RNAV8 Bio's collaboration is set to revolutionize the biopharma industry with mRNA-based advanced therapies. mRNA technology offers the potential to transform drug development by instructing cells to…
Unlocking the Future of Medicine: How a New Partnership is Revolutionizing mRNA Therapy
A groundbreaking partnership between Wacker Biotech and RNAV8 Bio aims to revolutionize mRNA-based therapies in biopharma. This collaboration combines Wacker Biotech's manufacturing prowess with RNAV8 Bio's advanced mRNA engineering techniques.…
The Game-Changing Partnership that Could Revolutionize mRNA Therapeutics
The joint venture between Wacker Biotech and RNAV8 Bio is advancing mRNA-based therapies. Focus is on optimizing mRNA untranslated regions (UTRs) to enhance drug stability and efficacy. Wacker Biotech's mRNA…
Eli Lilly’s Bold Move: A Lifeline for Gene Therapy’s Bleak Horizon?
Sangamo Therapeutics and Eli Lilly inked an $18 million deal to advance treatments for central nervous system diseases using Sangamo's STAC-BBB technology. The STAC-BBB capsid can effectively penetrate the blood-brain…
Trump’s Unexpected Tariff Twist Leaves Pharma Breathless but Buoyant
The pharmaceutical and biotech sectors exhibited resilience amid broad economic turmoil, largely unaffected by sweeping tariffs. Companies like Catalyst Pharmaceuticals and Veeva Systems experienced only minor stock declines, while Amgen…
Seattle’s Power Players: Meet the Innovators Reshaping the Future
Jill Angelo transitions from Unified Women’s Healthcare, leaving a legacy in menopause health awareness and telehealth services with Gennev. Aurion Biotech advances in cell therapies for eye diseases, bolstered by…
A Bold Move Against Epilepsy: How Neurona Therapeutics Plans to Defy the Odds
Neurona Therapeutics is advancing allogeneic cell therapy for drug-resistant mesial temporal lobe epilepsy (MTLE) with its promising NRTX-1001 therapy. Supported by a $102 million financing round, Neurona is navigating the…
Can Neurona’s Revolutionary Cell Therapy Transform the Future of Epilepsy Treatment?
Neurona Therapeutics has secured $102 million to advance its innovative cell therapy for epilepsy into phase 3 testing. The therapy, NRTX-1001, targets drug-resistant mesial temporal lobe epilepsy using GABAergic interneurons…
The Storm in Biotech: What’s Causing High-Flying Stocks to Plummet?
Early-stage biotech companies, including Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics, faced significant stock declines, with Biohaven down 35.3% in March's closing quarter. Biotech firms, often investment-heavy and loss-making, are struggling…